Introduction {#S0001}
============

Epidermodysplasia verruciformis (EV), a rare disease characterized by verrucous cutaneous lesions and spots resembling pityriasis versicolor which may progress to squamous cell carcinomas due to abnormal susceptibility to a specific group of oncogenic EV human papillomavirus (HPV), was first described in 1922 by Lewandowsky and Lutz \[[@CIT0001]\]. In 1933 Cockayne hypothesized that EV might be a congenital disease transmitted by a recessive gene \[[@CIT0002]\]. Later, clinical observations of familial aggregations in 147 reported cases supported this type of inheritance, because 10% of EV families have more than one affected sibling, the proportion of siblings was 25%, and the male to female ratio was close to 1 : 1 \[[@CIT0003]\]. However, there was one exception -- one consanguineous family in which only males developed EV and therefore X-linked recessive inheritance was also suggested, which could point to a genetic heterogeneity of the disease \[[@CIT0004]\]. In recent years two susceptibility loci for EV were mapped to chromosomal regions 17q25 (EV1) and 2p21-p24 (EV2) \[[@CIT0005], [@CIT0006]\], and this led to the identification of two novel genes, *EVER1* and *EVER2* in EV1, mutations in which play a role in development of EV \[[@CIT0007]\]. The role of EVER proteins remains unclear. Studies conducted to date to determine the function of the EVER proteins have shown that they have an ability to participate in maintaining the zinc balance in cells \[[@CIT0008]\].

The aim of this manuscript was to present the most important information and the results of the latest studies regarding *EVER* genes, their mutations and structures. The functions of EVER proteins and their role in HPV infections are also discussed.

*EVER* genes and their association with epidermodysplasia verruciformis {#S0002}
=======================================================================

In 1999 Ramoz *et al*. identified the first susceptibility locus for EV (named EV1). In cited studies, genetic analysis included three consanguineous EV families (2 originated from Algeria marked as A1 and A2 pedigree and 1 originated from Columbia marked as C1 pedigree), in which 6 individuals were diagnosed with EV. All affected people were born from first cousin marriages. A genome-wide linkage analysis using 255 highly polymorphic microsatellite markers spanning 22 autosomes was performed. It was found that the susceptibility locus for EV is located on chromosome 17q25, at a distance of 1 cM between the D17S939 and D17S802 markers \[[@CIT0005]\]. It needs to be stressed that the EV1 locus is situated in a larger region containing a locus for the susceptibility to psoriasis -- *PSORS2*, which was previously reported \[[@CIT0009]\]. It could explain the presence of EV HPV DNA in psoriatic papules in more than 90% of patients with psoriasis \[[@CIT0010]\].

In 2000 the same authors mapped the second susceptibility locus for EV (EV2). Genetic analysis was carried out in two consanguineous EV families from Columbia (C2) and France (F1) comprising 7 EV patients and their families, inclusively 27 individuals. The EV2 locus was mapped to the chromosome region 2p21-p24 at an 8 cM interval between the D2S171 and D2S2347 markers \[[@CIT0006]\]. The EV1 and EV2 loci included numerous genes encoding transcription factors, proteins involved in signal transduction and numerous expressed sequence tags \[[@CIT0011], [@CIT0012]\]. In 1999 Kuhlenbaumer *et al*. reported an integrated physical and partial transcript map of region 17q25 encompassing the EV1 locus \[[@CIT0013]\]. Also for the EV2 locus a map of the 1 cM region telomeric to the D2S174 marker has been reported. It is known that this region includes 5 genes and among them is the gene encoding the centromere protein A \[[@CIT0014]\]. Further studies allowed for the identification of the novel genes responsible for EV. The analysis included two previously described Algerian (A1 and A2) and two Colombian families (C1 and C2) and one additional Algerian family (A3). It was found that the EV1 region contains the following genes: thymidine kinase 1, synaptogyrin 2 and four novel genes named *EV1Xa*, *EV1Xb*, *EV1Xc* and *EV1Xd* \[[@CIT0015]\]. In the next stage, by RT-PCR in lymphoblastoid cell lines only *EV1Xc* and *EV1Xd* transcripts were obtained and assigned the symbols *EVER1* and *EVER2* respectively. These two adjacent novel genes are in the opposite orientation from the first inframe ATG codon and are separated by 4732 bp. The presence of these mutations in both *EVER1* and *EVER2* genes is associated with EV \[[@CIT0006]\].

*EVER* genes -- their structure, localization and correlations with the transmembrane channel-like (*TMC*) gene family {#S0003}
======================================================================================================================

The *EVER1* and *EVER2* genes are located on chromosome 17q25. The *EVER1* gene consists of 20 exons and 19 introns and encodes four transcripts. Two of the transcripts containing all exons have a length of 2891 bp and 2789 bp. The third contains 19 exons and is about 2711 bp in length. The last one contains 12 exons and is 1838 bp in length. The *EVER2* gene consists of 16 exons and 15 introns and encodes only one transcript of the length of about 4419 bp (<http://www.ensembl.org/Homo_sapiens/Transcript/>). In 2003 Keresztes *et al*. and Kurima *et al*. reported that the two newly detected *EVER1* and *EVER2* genes were identical to the *TMC6* and *TMC8* genes, respectively, and belonged to a novel gene family, the transmembrane channel-like gene family (*TMC*) \[[@CIT0016], [@CIT0017]\]. All *TMC* gene families consist of 8 genes, which encode transmembrane proteins with 6 to 10 domains. They also showed that all TMC proteins contain a 120-amino acid sequence, the TMC domain \[[@CIT0016], [@CIT0017]\]. The exact role of all *TMC* genes and their mutations is unknown. Besides *TMC6* and *TMC8* genes it was found that dominant and recessive mutations in the *TMC-1* gene and its murine ortholog-transmembrane cochlear expressed gene 1 (tmc-1), which is expressed in cochlear hair cells of the inner ear, cause hearing loss \[[@CIT0018]\].

Mutations and polymorphisms of *EVER* genes {#S0004}
===========================================

Mutations of the *EVER1* and *EVER2* genes were found in 31 (75.6%) of 41 EV patients in the course of a collaborative study \[[@CIT0019]\]. The fact that no mutations were detected in 25% of the EV patients indicates the genetic heterogeneity of the disease and may suggest not yet identified genes responsible for the development of the disease in some cases. So far in the literature there have been reported seven in *EVER1* and five in *EVER2* mutations resulting from several mechanisms: nonsense mutations, single nucleotide mutations, splice site mutation, or deletion of exons ([Table 1](#T0001){ref-type="table"}). In a group of Polish EV patients two mutations in the *EVER2* gene and lack of any mutations in the *EVER1* gene have been identified. The first mutation was transversion G\>T at nucleotide position 150 within intron 4. It has been assumed that this mutation (named IVS4-1G\>T; T150fsX3) is characteristic for the Polish population of patients with EV. The second mutation leads to the deletion of nucleotide T at position 705 within exon 8 (del705T, G235fsX47) (Majewski *et al*., data not shown). Besides mutations of *EVER* genes several polymorphisms have also been detected in EV. In the literature two polymorphisms of *EVER* genes registered in the dbSNP database in NCBI (rs7208422 and rs12452890) and one newly found (917 c. 457C→T) have been demonstrated \[[@CIT0020]--[@CIT0022]\].

###### 

Mutations of *EVER1* and *EVER2* genes

  Mutation of *EVER1* gene       Position (cDNA)       Exon       Intron       Reference
  ------------------------------ --------------------- ---------- ------------ -----------------------------------------
  1\. Nonsense                   220 C \> T            4          --           Aochi *et al*., 2007 \[[@CIT0041]\]
  2\. Nonsense                   280 C \> T            5          --           Ramoz *et al*., 2002 \[[@CIT0015]\]
  3\. Nonsense                   744 C \> A            8          --           Tate *et al*., 2004 \[[@CIT0042]\]
  4\. Splice-site                IVS8-2 A \> T         --         8            Tate *et al*., 2004 \[[@CIT0042]\]
  5\. Nonsense                   916insert CATGT       9          --           Zuo *et al*., 2006 \[[@CIT0022]\]
  6\. Frameshift                 968 delT              9          --           Gober *et al*., 2008 \[[@CIT0043]\]
  7\. Nonsense                   1726 G \> T           14         --           Ramoz *et al*., 2002 \[[@CIT0015]\]
  **Mutation of *EVER2* gene**   **Position (cDNA)**   **Exon**   **Intron**   **Reference**
  1\. Nonsense                   188 G \> A            3          --           Rady *et al*., 2007 \[[@CIT0044]\]
  2\. Fameshift                  561_583del            6          --           Berthelot *et al*., 2007 \[[@CIT0045]\]
  3\. Nonsense                   568 C \> T            6          --           Sun *et al*., 2005 \[[@CIT0046]\]
  4\. Frameshift                 754 delT              8          --           Ramoz *et al*., 2002 \[[@CIT0015]\]
  5\. Nonsense                   1084 G \> T           9          --           Ramoz *et al*., 2002 \[[@CIT0015]\]

EVER proteins -- their location and structure {#S0005}
=============================================

The full length transcripts of the *EVER1* gene encode two polypeptide chains consisting of 805 amino acids. In alternative splice events there are synthesized two isoforms consisting of two smaller proteins of length 384 and 454 amino acids ([www.ensembl.org/Homo_sapiens/Gene](http://www.ensembl.org/Homo_sapiens/Gene)). EVER1 protein is an integral membrane protein with ten domains ([www.cbs.dtu.dk/services/tmhmm-2.0](http://www.cbs.dtu.dk/services/tmhmm-2.0)), two leucine-zipper motifs and two putative glycosylation sites ([www.emboss.sourceforge.net/](http://www.emboss.sourceforge.net/)). The terminal regions of EVER1 protein are located lumenally to the cell membrane ([www.uniprot.org/help/uniprot](http://www.uniprot.org/help/uniprot)). The *EVER2* gene contains one transcript of length 4419 bp, which encodes one protein of 726 amino acids. The EVER2 protein is also an integral membrane protein, which contains eight domains, three leucine-zipper motifs and two putative glycosylation sites. Terminal regions of the EVER2 protein are located on the cytoplasmic side of the cell as distinct from EVER1. EVER1 and EVER2 proteins are 28.3% identical in their features, and less conserved sections are present in their amino and carboxyl termini. The proteins are expressed in the cytoplasm and co-localized with calnexin, which is an integral membrane protein present in the endoplasmic reticulum \[[@CIT0015]\]. The *EVER* genes are transcribed in keratinocytes, CD4+ and CD8+ lymphocytes, B lymphocytes and NK cells. It has also been shown that EVER1 proteins are present in endothelial cells, CD 33+ myeloid cells and dendritic cells \[[@CIT0023]\]. It needs to be stressed that in lymphoid cells the expression of *EVER1* and *EVER2* is higher than in the skin \[[@CIT0024]\].

The role of EVER proteins in the immune system {#S0006}
==============================================

The characteristic phenomenon in EV is impaired cell-mediated immunity leading to the persistence of established EV HPV infections and to the malignant transformation of some of the lesions \[[@CIT0024]\]. In several studies a decreased T-cell count, defective T-cell proliferation in response to phytohemagglutinin (PHA) and cutaneous anergy to a variety of antigens have been reported. It is known that patients with EV overproduce tumor necrosis factor α (TNF-α) in lesions and have a defect in AP-1 signaling in keratinocytes which are controlled by TNF receptor 1 (TNFR-1) \[[@CIT0025]\].The burning question is what might be the specific role of *EVER* genes in creating immune responses and the consequence of the mutations of *EVER* genes for the function of lymphocytes. It has been observed that *EVER* genes are transcribed not only in the human skin but also in CD4+ and CD8+ T lymphocytes, B lymphocytes and NK cells at high levels. The expression in immune system cells could point to their involvement in the immune response \[[@CIT0024]\]. It is also speculated that the deficiency of EVER proteins in T-cells may contribute to susceptibility to HPV infections due to impairment of the immune response. Indeed the recent study carried out on circulating lymphocyte populations in three adult EV patients sharing the same EVER2 mutation (T150fsX3) showed mild T-cell abnormalities. The researchers observed a significant increase of memory CD4+ and effector memory CD8+ T cells, a bias of the TCR Vαβ and Vγδ repertoires and an increase of skin-homing CD4+ T-cell subsets. The count of CD4+ and CD8+ T cells and the proliferative capacity in response to anti-CD3 stimulation were normal \[[@CIT0025]\]. Another study showed that activated CD4+ and CD8+ lymphocytes (via the TCR receptor) decreased expression of EVER proteins with accompanying accumulation of zinc ions in the cytoplasm \[[@CIT0024]\].

The role of EVER proteins in keratinocytes {#S0007}
==========================================

The role of proteins encoded by *EVER* genes was unknown until the demonstrations carried out by Lazarczyk *et al*., who reported that EVER proteins might be responsible for the regulation of cellular zinc balance \[[@CIT0008]\]. It is known that zinc is an important ion crucial for the proper functions of numerous proteins such as enzymes \[[@CIT0026]--[@CIT0028]\], signal transduction proteins and transcription factors. The authors found that EVER proteins interact with ZnT-1 (Zn transporter) and form the complex ZnT-1/EVER, which is associated with transferring the zinc from the cytoplasm into the endoplasmic reticulum (ER) lumen, decreasing the total amount of zinc in the cytoplasm and indirectly in the nucleus. The precise role of EVER proteins within the ZnT-1/EVER complex has not been determined yet. It is hypothesized that EVER proteins may act by: (i) modulating the activity of ZnT-1 or (ii) serving as zinc transporters themselves. It has been determined that a mutation in one of the *EVER* genes (regardless of whether *EVER1* or *EVER2*) interrupts the function of the whole ZnT-1/EVER complex and leads to a flux in the reverse direction from ER to the cytoplasm and the nucleus \[[@CIT0008]\]. The discovery of the molecular mechanism of EVER proteins in maintaining zinc homeostasis suggests that the ZnT-1/EVER complex participates in the regulation of the activity of many transcription factors. Indeed, upon further investigation it was found that the ZnT-1/EVER complex suppressed the activity of the AP-1, Elk-1 and Fos transcription factors in keratinocytes \[[@CIT0029]\]. Moreover, the suppression of AP-1 by the ZnT-1/EVER complex is also determined when AP-1 is activated by other physiological triggers such as epidermal growth factor (EGF) and tumor growth factor α (TGF-α) \[[@CIT0030]\]. It seems that cellular phosphatase and kinases might be the crucial target for the ZnT-1/EVER complex and in this way reflect the phosphorylation status of numerous cellular proteins \[[@CIT0029]\].

It needs to be stressed that the results of the latest studies suggest other functions of EVER proteins. Studies carried out by Gaud *et al*. showed the role of EVER proteins in inducing cell apoptosis. It was determined that EVER2 protein binds TRADD and promotes TNF-α and TRAIL-induced apoptosis. In this process the EVER2 protein interacts with the N-terminal domain of TRADD, and impairs the recruitment of TRAF2 and RIPK1 \[[@CIT0031]\].

In 2014 Vuillier *et al*. analyzed the role of EVER2 protein in NF-κB and JNK/AP-1 signaling pathways. Interestingly, the results showed that EVER2 loss induces constitutive JNK activation, impairs the NF-κB pathway, sustains TRAF2 ubiquitination and decreases the pool of TRAF2. Finally, the authors demonstrated that EVER2 loss induces constitutive PKCa-dependent c-jun phosphorylation. These findings may indicate that mutations of the *EVER2* gene may create the way to EV HPV replication and the persistence of lesions with the potential to develop into skin cancer \[[@CIT0032]\].

The role of EVER proteins in HPV infections {#S0008}
===========================================

The role of the "EVER barrier" in EV HPV infections in EV and the general population also remains a mystery. It is hypothesized that properly functioning zinc homeostasis might constitute a natural protective barrier, which limits the access of zinc ions and prevents viral replications \[[@CIT0029]\]. In EV, mutations of *EVER* genes lead to the synthesis of impaired EVER proteins and disrupt the ZnT-1/EVER complex, leading to an increased zinc level in the cytoplasm, allowing replication of EV HPV ([Figure 1](#F0001){ref-type="fig"} A) and unusual sensitivity to infections by EV HPV \[[@CIT0029]\]. The intriguing question is in what way does the lack of properly functioning EVER proteins in EV lead to EV and skin cancers? It has been proposed that excess of zinc ions may induce c-Jun related pathways and the transcriptional activity of AP-1. It has been proved that the AP-1 factor is crucial for expression of the viral genome \[[@CIT0033]\].

![Mechanism of action of EVER proteins in keratinocytes: **A** -- infection of keratinocytes by genital HPV (HPV16) leads to synthesis of E5 protein and inhibition of the ZnT-1/EVER complex, which allows viral replication in the general population, **B** -- lack of synthesis of E5 protein by EV-HPV protects against infections in the general population, **C** -- in epidermodysplasia verruciformis mutations of EVER genes lead to impairment of the ZnT-1/EVER complex, allowing EV HPV infections](PDIA-33-27312-g001){#F0001}

The next intriguing question is why in healthy people without mutations in *EVER* genes and with properly functioning EVER proteins the genital HPV viruses have the ability to induce various anogenital lesions, even such as cervical cancer. The answer can be proposed by two hypotheses. According to the first one, the EVER-based barrier might be highly selective and concern EV HPV, not genital HPV; and according to the second, the EVER-based barrier is equal for both EV HPV and genital types, but genital HPVs probably develop a mechanism that facilitates their elusion of this barrier. Currently the second hypothesis seems to be more likely. The breakthrough was found in the role of the viral protein E5. Interestingly, the E5 protein is expressed only by genital HPV and not by EV HPV \[[@CIT0034]\]. This protein is assumed to contribute to the development of a lesion by stimulating cell division \[[@CIT0035]\]. ZnT-1/EVER was found to bind the E5 protein, leading to an increase in concentration of free zinc in keratinocytes and allowing for the replication of genital HPV ([Figure 1](#F0001){ref-type="fig"} B). In non-EV patients the lack of E5 protects against EV HPV infections ([Figure 1](#F0001){ref-type="fig"} C) \[[@CIT0029]\].

The role of polymorphism of *EVER* genes in carcinogenesis {#S0009}
==========================================================

So far in the literature there have not been any reported mutations of the *EVER* genes in any disorders other than EV. It needs to be stressed that there is an available report showing a link between polymorphism in the *EVER* genes and carcinogenesis. Patel *et al*. \[[@CIT0036]\] showed a link between the genetic variation in the *EVER2* gene and an elevated risk of squamous cell carcinoma (SCC). This study was based on the hypothesis that *EVER* genes, mutations of which play a key role in skin cancers in EV, may also be impaired in carcinogenesis in non-EV patients. It is also known that EV HPV DNA is detected in a high percentage of actinic keratosis (AK) (85%) and SCC (45%) cases \[[@CIT0037]\]. It needs to be stressed that only 30--40% of EV patients develop non-carcinoma skin cancers. The clinical phenotype of EV is dependent on viral and immunological features that characterize EV patients. It could also point to the possible genetic heterogeneity of the disease \[[@CIT0007]\]. Patel *et al*. showed that genotype TT of polymorphism rs7208422 (c.917A→T, p.N306l) in *EVER2* is related to a 70% increase in the risk of SCC compared to the controls (OR = 1.7; 95% CI = 1.1--2.7; *p* = 0.01). It has also been associated with seropositivity for b-HPV5 and -8, and SCC \[[@CIT0036]\]. In our latest studies we also found a possible association between AK and rs7208422 TT (frequency of TT in AK was 38.5% and 26.3% in the controls, OR = 1.75, *p* = 0.056 for recessive model of inheritance). This study could point to the potential role of polymorphism rs7208422 (c.917A→T, p.N306l) of the *EVER2* gene in AK \[[@CIT0038], article in press\]. The exact mechanism of this polymorphism in carcinogenesis remains unknown, but in a recent study Gaud *et al*. demonstrated that the skin cancer-associated EVER2 306l protein coded by T alleles results in impaired TRADD--EVER2 interaction with lower levels of TNF-α apoptosis \[[@CIT0031]\]. The concept of the role of polymorphisms of the *EVER* genes in carcinogenesis was also analyzed in cervical cancer, in which experimental and epidemiological studies have demonstrated, similarly to EV, the role of oncogenic HPV in its development. Up to now there are two publications available which assess polymorphisms of the *EVER* genes in this disease. Wang *et al*. found that some regions of the *EVER* genes are significantly correlated with the presence of cervical intraepithelial neoplasia III \[[@CIT0039]\]. Studies carried out by Castro *et al*. showed a strong association between rs2290907 and rs16970849 in *EVER* genes and cervical cancers \[[@CIT0040]\].

Summary {#S0010}
=======

The discovery of the role of the *EVER1* and *EVER2* genes has led to better understanding of processes of skin carcinogenesis. Therefore, further research evaluating the relationships between the EVER genes, the mechanism of action of EVER protein and HPV is required to fully elucidate skin carcinogenesis.
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